NCT01257607View on ClinicalTrials.gov

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Dry Eye
Interventions
DRUG

MIM-D3 Ophthalmic Solution

28 Days, BID

DRUG

Placebo Ophthalmic Solution

28 Days, BID

Trial Locations (1)

01830

Ora, Inc., Andover

Sponsors
All Listed Sponsors
lead

Mimetogen Pharmaceuticals USA, Inc.

INDUSTRY